Short Interest Reporting: Threshold Pharmaceuticals Incorporated (NASDAQ:THLD) Could Burn Your Long Portfolio After More Shorts

November 17, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Reporting: Threshold Pharmaceuticals Incorporated (NASDAQ:THLD) Could Burn Your Long Portfolio After More Shorts

The stock of Threshold Pharmaceuticals Incorporated (NASDAQ:THLD) registered an increase of 64.27% in short interest. THLD’s total short interest was 1.66 million shares in November as published by FINRA. Its up 64.27% from 1.01M shares, reported previously. With 5.90M shares average volume, it will take short sellers 0 days to cover their THLD’s short positions. The short interest to Threshold Pharmaceuticals Incorporated’s float is 2.53%. About 444,879 shares traded hands. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) has declined 8.33% since April 15, 2016 and is downtrending. It has underperformed by 12.96% the S&P500.

Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company has a market cap of $30.33 million. The Firm is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It has a 0.8 P/E ratio. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

THLD Company Profile

Threshold Pharmaceuticals, Inc. (Threshold), incorporated on October 17, 2001, is a clinical-stage biotechnology company. The Firm is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Firm is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

More news for Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) were recently published by: Marketwatch.com, which released: “Threshold Pharmaceuticals’ stock plunges after drug trial disappoints” on December 07, 2015. Streetinsider.com‘s article titled: “Threshold Pharma (THLD) Says Two Studies Didn’t Meet Activity Thresholds …” and published on September 29, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>